Literature DB >> 22068365

Challenges and lessons learned from the translation of evidence-based childhood asthma interventions: a commentary on the MCAN initiative.

Yvonne U Ohadike1, Floyd J Malveaux, Julie Kennedy Lesch.   

Abstract

The Merck Childhood Asthma Network (MCAN) used evidence-based interventions (EBIs) for children with asthma to design community-based programs in a wide variety of settings--with varying resource constraints and priorities--that were often determined by the program context. Although challenges were faced, lessons learned strongly suggest that adapting and implementing EBIs is feasible in a variety of settings using a multisite approach. Lessons learned during the MCAN initiative presented unique opportunities to refine best practices that proved to be important to translation of EBIs in community-based settings. The adopted best practices were based on experiential learning during different phases of the project cycle, including monitoring and evaluation, translational research, and implementing policies in local program environments. Throughout this discussion it is important to note the importance of program context in determining the effectiveness of the interventions, opportunities to scale them, their affordability, and the ability to sustain them. Lessons learned from this effort will be important not only to advance science-based approaches to manage childhood asthma but also to assist in closing the gap between intervention development (discovery) and program dissemination and implementation (delivery).

Entities:  

Mesh:

Year:  2011        PMID: 22068365     DOI: 10.1177/1524839911414565

Source DB:  PubMed          Journal:  Health Promot Pract        ISSN: 1524-8399


  1 in total

1.  A Mixed-Method Application of the Program Sustainability Assessment Tool to Evaluate the Sustainability of 4 Pediatric Asthma Care Coordination Programs.

Authors:  Shelley Stoll; Mary Janevic; Marielena Lara; Gilberto Ramos-Valencia; Tyra Bryant Stephens; Victoria Persky; Kimberly Uyeda; Yvonne Ohadike; Floyd Malveaux
Journal:  Prev Chronic Dis       Date:  2015-12-03       Impact factor: 2.830

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.